Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
80.14
+1.14 (+1.44%)
Streaming Delayed Price
Updated: 10:51 AM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Gilead Sciences to Present at Upcoming Investor Conferences
August 21, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
August 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Second Quarter 2024 Financial Results
August 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
July 24, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
July 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
July 17, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
July 16, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
MarketBeat Week in Review – 6/17 - 6/21
June 22, 2024
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Gilead Sciences Stock Surges on HIV Treatment Trial Success
June 21, 2024
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial.
Via
MarketBeat
Exposures
Product Safety
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
June 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
June 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
June 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
June 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Provides Update on Phase 3 TROPiCS-04 Study
May 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
May 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
May 18, 2024
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May...
Via
PRLog
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
May 18, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
May 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
May 07, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.